Mysterious Fog in the US , Canada and UK: A dense, eerie fog with a "burning chemical-like smell" has spooked a good part of North America and parts of the United Kingdom and Canada. With social media amplifying all concerns, this phenomenon has sparked attention across all social media platforms. However, at the heart of this mysterious fog are a conjunction of natural events, social psychology, and environmental conditions that culminated in all the conspiracy theories and public health fears. Here's a closer look at the mysterious fog, its potential causes, and the societal response it has triggered.

Fog that Feeds Fear

The first reports of this "mysterious fog" came in from Florida where a resident said that they experienced respiratory symptoms, feverish warmth, and stomach cramps after contact with the fog. Similar stories started flooding social media, and within a day or two, a sinister force seemed to sweep across the United States, Canada, and parts of the UK. From Texas to Minnesota, people reported weird odors and health issues that they thought were linked to this bizarre atmospheric event.

Some witnesses were said to see "white particles" swirling through the air; theories ranged from a chemical attack or experimental weapon to drone-related chemical dispersals and references to historical military experiments, such as the infamous 1950s "Operation Sea-Spray."

Fuel to the fire were added when videos and posts, hundreds of thousands in number, began circulating on social media sites like TikTok and X (formerly Twitter) speculating on the origin of the fog. Hashtags like #ToxicFog went trending for days. Hysteria created a self-reinforcing loop in which every post spurred further scrutiny and fear.

Scientific Explanation of the Dense Mysterious Fog

1. What is Fog?

Fog is essentially a low-lying cloud formed when the air temperature cools to its dew point, causing water vapor to condense into tiny droplets or ice crystals. Several types of fog—advection fog, radiation fog, and valley fog—can form depending on conditions such as warm, moist air moving over cooler land or when temperatures plummet rapidly under clear skies.

2. Why the Chemical Smell?

Such chemical-like smell as reported during the occurrence of fog events is sometimes attributed to air pollution. It acts like a sponge, where it absorbs these pollutants, which include sulfur dioxide and nitrogen oxides, among others, that emit from industries. This mixture, therefore, leads to a stench that could be mistaken as unnatural or even toxic.

Also Read: Health Concerns Rise As US, Canada, and UK Come Under The Blanket Of Thick, Dense, Toxic Fog

3. What are the Health Concerns?

High moisture levels from fog can significantly exacerbate symptoms related to respiration, but especially in already predisposed asthmatics and allergy patients. The connection of these symptoms with actual fever, stomach cramps, and puffy eyes is too remote. Experts assume that the irritating effects of entrapped pollutants trapped in fog tend to affect more the eyes and throat rather than the rest of the body affected by some report.

Psychological Effects of Mass Panic Caused by Social Media

Social media amplified a natural weather event into a health epidemic. It made the personal experience of individuals become a cause for fear and speculation, a domino effect.

According to psychologists, this is a concept of selective perception, wherein once people's attention is drawn to environmental anomalies, they begin to notice them. This mirrors earlier panics, such as the Seattle windshield pitting panic of 1954. Then, atomic bomb testing caused fear in many and started to have people looking at their windshields for small marks that they had not seen before. Likewise, postings on the strangeness of the fog probably increased public awareness and suspicion, with people looking to attach unrelated symptoms to the phenomenon.

The fog hysteria shares a commonality with other instances of mass panic, such as the "drone sightings" of recent years or the Cold War-era fears of biological warfare.

Also Read: Mysterious Fog Is Making Americans Sick

These events underscore how fear can cloud judgment, especially when amplified by social media and sensationalist headlines. While historical cases, such as "Operation Sea-Spray," offer concrete evidence of the existence of unethical experiments, the jump from a natural weather condition to theories of chemical attacks exemplifies a more modern trend of connecting unrelated dots, all wonderfully seeded in distrust and anxiety.

Despite the swirling rumors, meteorologists and scientists are in agreement that the mysterious fog is not as alarming as it seems. It is well known that fog traps and amplifies pollutants, especially in urban and industrial regions. Moreover, winter months are the most conducive for fog formation, so its recent prevalence is unsurprising.

On the other hand, environmentalists advise that the fog should wake everyone up to increased levels of pollution. The reported odors and health irritations could be just symptoms of far deeper systemic issues like industrial emissions and lack of control over air quality.

The authorities must be transparent in their communication to combat misinformation and allay public fears. Governments and environmental agencies must provide timely updates on weather phenomena, air quality, and health risks. Initiatives like real-time pollutant tracking and public education campaigns can help demystify natural occurrences while addressing valid environmental concerns.

The mysterious Canada fog is a compelling case study in how environmental events intersect with psychology and societal dynamics. While rooted in natural phenomena, the fog became a vessel for collective fears, amplified by modern technology and historical anxieties.

In this information era where communication occurs at an almost lightning pace, the fog becomes a metaphor that reminds everyone about scientific literacy, environmental responsibility, and an effective balance when considering public concern. Whether perceived as a marvel of nature or as a tale that serves to teach, it left a very powerful mark in people's minds.

Col Anurag Upadhyay, a former Indian Army officer and Special Forces veteran, is living with locked-in syndrome, a rare neurological condition in which a person can remain conscious and aware while losing the ability to speak and move most muscles.

While there is currently no medicine or injection proven to reverse established locked-in syndrome, experts stress the importance of specialized neurorehabilitation, communication aids and appropriate assistive technologies.

Col Anurag’s Journey

A decorated Army officer and Special Forces veteran, Col Upadhyay suffered a severe posterior circulation stroke in August 2025. The stroke reportedly caused extensive neurological damage and left him with locked-in syndrome.

Despite being unable to move or speak normally, Col Upadhyay is conscious and aware. According to a social media post seeking medical and rehabilitation support for him, he communicates complete thoughts through eye movements and an alphabet-based scanning system.

Also read: Bill Ackman’s Daughter Gets Experimental Treatment For Vision Loss: When Can Mitochondrial Transplants Help?

What Is Locked-In Syndrome?

Cleveland Clinic defines the syndrome as "a rare and serious neurological disorder that causes complete paralysis of all voluntary muscles except for the eyes, while leaving the person fully conscious and aware"

“Locked-in syndrome is one of the most devastating neurological conditions,” said Dr Sudhir Kumar, neurologist at Apollo Hospitals, Hyderabad, in a post on social media platform X.

The condition can leave a person unable to speak or move most muscles despite remaining conscious and aware.

It can severely affect communication and physical independence. However, the extent of impairment and potential for recovery can vary depending on the cause, location and severity of the brain injury, as well as whether the syndrome is complete or incomplete.

Is There A Medicine To Reverse It?

Dr Kumar said, “The honest answer is: There is currently no medicine or injection proven to reverse established locked-in syndrome.”

However, the absence of a proven medicine does not mean that supportive treatment and rehabilitation have no role.

Even after 13 months, Dr Kumar strongly recommended assessment at a specialised centre with experience in long-term neurorehabilitation and assistive technology.

Why Neurorehabilitation and Communication Matters

Read More: Pig Kidney Works In Human Body For 271 Days: Why Xenotransplants Could Bridge The Organ Transplant Gap

Dr Kumar recommended a detailed reassessment by a multidisciplinary team that could include a neurologist, rehabilitation physician, physiotherapist, occupational therapist, speech and swallowing therapist, respiratory therapist, psychologist and specialist nurses.

Such an assessment can help identify even small voluntary movements that may have been missed or may have emerged over time.

He also recommended intensive, individualised neurorehabilitation focused on maintaining joint mobility, preventing contractures, improving head and trunk control, increasing sitting tolerance and supporting any residual voluntary movement.

“Even a small movement of a finger, thumb, head or eye can sometimes become functionally very important,” Dr Kumar said.

For people with locked-in syndrome, establishing a reliable way to communicate can be particularly important.

Dr Kumar stressed that “communication should be a top priority” and recommended considering an eye-gaze or eye-tracking communication system where appropriate.

“Restoring a reliable means of communication can dramatically improve autonomy and quality of life,” he said.

Swallowing, Respiratory Care And Mental Health

Dr Kumar also suggested “periodic reassessment of swallowing and bulbar function” and “speech-language therapy”, along with “chest physiotherapy, respiratory exercises, secretion management and periodic reassessment of ventilatory requirements”.

Emphasising the importance of mental health and quality of life, he said, “Never assume that a person with locked-in syndrome does not understand what is happening around them.”

What New Technologies Could Offer

Dr Kumar also highlighted “exciting ongoing research” into several technologies that could potentially improve communication, interaction and rehabilitation for people with severe paralysis.

These include:

1. Eye-tracking and advanced communication systems
2. Brain-computer interfaces (BCIs) that translate brain signals into computer commands
3. BCI-assisted communication for people with severe paralysis
4. Robotics and functional electrical stimulation
5. Virtual reality and technology-assisted rehabilitation
6. Non-invasive brain stimulation, such as transcranial direct current stimulation, currently being explored as an adjunct to rehabilitation

However, these technologies should not be presented as established treatments for locked-in syndrome.

“These technologies are promising, but it is important to be realistic: most are not yet proven treatments capable of reliably reversing locked-in syndrome,” Dr Kumar said.

For people living with locked-in syndrome, continued access to evidence-based rehabilitation, communication tools, assistive technologies and specialised care can remain important.

“For a man who has served our country, we owe him continued care, respect and access to every evidence-based opportunity for rehabilitation,” Dr Kumar said.

“There may not be a miracle medicine today. But there is still meaningful medicine to be practiced and meaningful hope to be offered.”

Tozorakimab, an investigational drug developed by AstraZeneca, reduced moderate-to-severe flare-ups of chronic obstructive pulmonary disease (COPD) in two late-stage trials, the company has announced.

Presented at the ongoing European Respiratory Society Congress in Barcelona, the results showed that patients receiving tozorakimab experienced about 29% to 34% fewer COPD exacerbations over one year compared with placebo, when added to standard inhaled therapy.

The results, also published in the New England Journal of Medicine, showed that the drug was generally well tolerated, with injection-site reactions reported as the only adverse drug reaction.

Researchers from the University of Pittsburgh who led the trials said the findings highlight tozorakimab’s potential as a treatment for people with COPD who remain at risk of exacerbations despite standard inhaled therapy.

What Is Tozorakimab?

Tozorakimab is a potential first-in-class monoclonal antibody targeting interleukin-33 (IL-33).

The drug is designed to inhibit signalling from both the reduced and oxidised forms of IL-33, with the potential to reduce inflammation and disrupt the cycle of mucus dysfunction that contributes to COPD worsening.

AstraZeneca is developing tozorakimab as an add-on maintenance treatment for adults with COPD.

What Did the COPD Trials Find?

The findings come from two replicate Phase 3 trials, OBERON and TITANIA, which included a total of 2,306 adults with symptomatic COPD who were current or former smokers and had a history of exacerbations despite stable standard-of-care inhaled maintenance therapy.

Tozorakimab 300 mg, given once every four weeks, reduced moderate-to-severe COPD exacerbations among former smokers by:

• 29% in OBERON

• 34% in TITANIA

In the overall population of current and former smokers, exacerbations were reduced by:

• 30% in OBERON

• 29% in TITANIA

The reductions were compared with placebo while patients continued inhaled standard-of-care treatment.

A pooled analysis of the two trials also showed clinically meaningful reductions across all prespecified patient subgroups, including those defined by blood eosinophil count (BEC).

Patients with a baseline BEC below 150 achieved a 23% reduction in moderate-to-severe exacerbations, while those with a BEC of 150 or higher achieved a 34% reduction. Among patients with a BEC of 300 or higher, the reduction was 43%.

“Today’s groundbreaking tozorakimab results, from two replicate trials, set a new standard for COPD treatment outcomes in a broad population of patients. AstraZeneca has clinically validated the novel approach of targeting the signalling of the two forms of IL-33 to both decrease inflammation and disrupt the cycle of mucus dysfunction. With our FDA Priority Review, we look forward to bringing this treatment to patients as quickly as possible,” said Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca.

What Happens Next?

The Biologics License Application for tozorakimab 300 mg, administered once every four weeks, has been accepted by the US Food and Drug Administration for Priority Review as an add-on maintenance treatment for adults with COPD.

Tozorakimab is also under regulatory review for COPD in major markets, including the EU and China.

The drug is being studied in a Phase II trial for severe asthma and a Phase III trial for severe viral lower respiratory tract disease. It received FDA Fast Track Designation for severe viral lower respiratory tract disease in November 2023 and for COPD in December 2024.

Why COPD Flare-Ups Matter

COPD is the third leading cause of death worldwide, excluding COVID-19. It is a progressive respiratory condition characterized by persistent airflow limitation and chronic inflammation of the airways.

Common symptoms include breathlessness, chronic cough, and excess mucus production.

COPD exacerbations can worsen these symptoms and contribute to ongoing inflammation and bronchoconstriction, making it difficult to breathe. They can also accelerate disease progression, increase hospitalizations and raise the risk of future cardiopulmonary events, including heart attacks.

In the US, COPD exacerbations cause more than 2,500 emergency department visits each day. Only 50% of COPD patients live more than 3.5 years after their first severe exacerbation.

Bangladesh was once close to eliminating measles but is now battling what has been described as the world’s largest measles outbreak. With close to 1,000 suspected and confirmed measles-related deaths since March 2026, the country is grappling with its worst outbreak.

According to Bangladesh health ministry data cited by Reuters, 999 deaths have been associated to the measles outbreak, including 100 laboratory-confirmed measles fatalities.

More than 166,000 suspected cases have been reported, including nearly 20,000 laboratory-confirmed infections. More than 146,000 suspected patients have also been hospitalised.

Bangladesh, who is already battling a worsening dengue crisis, is dealing with enormous strain on its healthcare system.

How Did Bangladesh Go From Near Elimination To A Massive Outbreak?

Measles is one of the world’s most contagious infectious diseases. It spreads through respiratory droplets and airborne particles when an infected person coughs, sneezes or breathes. But measles is also highly preventable through vaccination.

For much of the past decade, Bangladesh maintained measles vaccination coverage at or above the 95% level recommended by the World Health Organization (WHO) for preventing long-term transmission.

The vaccine coverage dropped during the COVID-19 pandemic, but the country had otherwise made substantial progress toward elimination.

The political upheaval in 2024 and 2025 disrupted routine immunisation which contributed to the current crisis.

Bangladesh’s health minister, Sardar Md. Sakhawat Husain, told parliament that changes in vaccine procurement contributed to shortages.

A vaccination programme was postponed in 2024, while a nationwide measles-rubella campaign planned for the following year was cancelled, according to Reuters. That left growing numbers of children without adequate immunity.

“Bangladesh missed its measles elimination target because of vaccination gaps in 2024 and 2025,” said Professor Mahmudur Rahman, an epidemiologist and former director of the Institute of Epidemiology, Disease Control and Research.

Also read: RFK Jr. Accepts Pennsylvania Child’s Measles Death After Questioning It: Here's Why

Young Children Bearing The Brunt

Children under five have been particularly affected, making up for about 80% of cases during the initial stages of the outbreak.

Infants are especially vulnerable because babies younger than nine months may be too young to receive the routine measles vaccine, according to the country’s vaccine schedule.

When vaccination coverage falls in older children and adults, the virus can circulate more widely, increasing the chances that infants will encounter it before they are protected.

Measles itself can cause high fever, cough, runny nose and the characteristic rash. But the danger comes from its complications.

Children can develop pneumonia, severe dehydration, ear infections and encephalitis, or inflammation of the brain. Malnutrition can make severe disease more likely.

“To my knowledge, Bangladesh has never witnessed so many children dying from measles. Nor have we ever seen such a high number of patients in a single year. This is a truly terrible situation, and the saddest part is that the victims are children,” Rahman said.

Also read: HHS Announces US FDA’s First AI Chief: Here’s What It Means For The Future Of Drug Regulation

Bangladesh Has Started A Massive Vaccination Response

The government launched an emergency measles-rubella vaccination campaign in April, supported by international health agencies.

More than 19.7 million children have been vaccinated through the campaign, according to Reuters. But public health experts say emergency campaigns alone cannot solve the problem.

The country also needs to restore routine childhood immunisation, identify children who missed earlier doses and close the immunity gaps that allowed the virus to spread so rapidly.

UNICEF had already warned in April that the outbreak was disproportionately affecting young children. Its early situation report recorded nearly 10,000 suspected cases and 128 suspected measles-related deaths by April 7, highlighting how quickly the outbreak escalated.